<div id="readability-page-1">05:30 PM EST, 01/20/2026 (MT Newswires) -- BioAge Labs ( BIOA ) reported late Tuesday that it plans to launch a public offering of up to $75 million of common shares.Underwriters will be given a 30-day option to buy an additional $11.3 million of shares of its common stock, the company said.The biopharma company said it plans to use the proceeds from offering, along with its existing cash, to finance the advancement of its product candidates, including lead candidate BGE-102, for debt reduction and general corporate purposes, among others.Shares of the company fell more than 5% in recent after-hours activity. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

BioAge Labs 计划公开发行最多 7500 万美元的普通股，承销商有 30 天的选择权可增发 1130 万美元。这些资金将用于推进产品候选者的开发，包括 BGE-102、减少债务以及一般企业用途。在公告发布后，股价在盘后交易中下跌超过 5%

BioAge Labs Proposes Public Offering Worth $75 Million

fidelity

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

BioAge Labs

BioAge Labs 提议进行总额为 7500 万美元的公开发行